Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
The AI response includes several high-level safety/infection statements that are directionally consistent with labeled infection risk, but it also makes multiple broad generalizations about long-term safety themes, absence of new signals, and cross-class/comparative interpretations that are not supported by the provided COSENTYX prescribing information excerpts and therefore cannot be verified against the label.
Category Scores
Accurate Statements
Secukinumab/Cosentyx may increase the risk of infections.
Label Section 5.1 (Infections): "COSENTYX may increase the risk of infections... higher rates of common infections" and postmarketing reports of opportunistic infections including fungal infections.
In postmarketing settings, serious opportunistic infections including fungal infections have been reported with IL-17 inhibitors including COSENTYX.
Label Section 5.1 (Infections) and Section 6.2 (Postmarketing Experience): reports include "opportunistic infections including" fungal infections (and other serious infections).
If a patient develops a serious infection, monitoring and discontinuation until resolution are addressed in the label.
Label Section 5.1 (Infections): "If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves."
Unsupported Statements
Long-term safety for secukinumab has been followed through multi-year clinical follow-up and safety monitoring programs.
The provided label excerpts do not contain a claim specifically describing multi-year clinical follow-up/safety monitoring programs as stated.
Over longer follow-up, adverse events observed over time generally stay consistent with what was observed earlier in treatment.
The provided label excerpts do not support a general statement that adverse events remain generally consistent over time in longer follow-up.
No new major safety signal has emerged in longer follow-up studies of secukinumab.
The provided label excerpts do not state that no new major safety signal has emerged.
In secukinumab use, upper respiratory infections are observed.
The label excerpt indicates higher rates of common infections but does not specifically state upper respiratory infections as such.
In some studies of secukinumab, candidiasis events occur more frequently.
The provided label excerpts mention opportunistic fungal infections but do not state that candidiasis occurs more frequently in studies.
Serious adverse events and discontinuations for secukinumab are tracked over time.
The provided label excerpts do not state that serious AEs/discontinuations are tracked over time in the manner claimed.
Rates of serious adverse events and discontinuations for secukinumab are reported as comparable to expectations for this treatment class in long-term follow-up datasets.
No such comparative, class-expectation statement appears in the provided label excerpts.
Direct apples-to-apples long-term comparisons across drugs are limited because trials differ in populations, dosing, background therapies, study duration, and how events are captured.
This is a methodological generalization not supported by the provided label excerpts.
Among IL-17 inhibitors, infection-related events (including mucocutaneous fungal infections like Candida) are key long-term safety themes.
The label excerpt supports infection risk and reports of opportunistic fungal infections, but does not support the framing of "key long-term safety themes" or "including mucocutaneous fungal infections like Candida" as a specific long-term theme.
Among IL-17 inhibitors, there is an absence of a pattern of unexpected late-emerging toxicities in long-term extensions.
The provided label excerpts do not state absence of late-emerging toxicities.
For comparisons between secukinumab and other IL-17 drugs (such as brodalumab or ixekinumab), the long-term safety story is usually similar in kind.
The provided label excerpts do not include comparative statements about other IL-17 drugs.
TNF inhibitors have long-term safety considerations that often include emphasis on serious infections and reactivation risk patterns associated with TNF suppression.
Comparative statements about TNF inhibitors are not present in the provided COSENTYX label excerpts.
IL-17 inhibitors tend to be described as focusing rather than on the same reactivation concerns traditionally highlighted for TNF inhibitors.
Not supported by the provided label excerpts.
IL-23 inhibitors have a long-term safety profile that is considered consistent and has been monitored for multi-year outcomes.
Not present in the provided COSENTYX label excerpts; no IL-23 comparative content is included.
Patients and clinicians monitor malignancy and major cardiovascular events over time when interpreting long-term risks with biologics.
The provided label excerpts do not state this as a monitoring theme/claim.
Immunogenicity (anti-drug antibodies) is tracked over multi-year periods for biologics and can affect long-term safety or effectiveness.
The provided label excerpts do not include immunogenicity/anti-drug antibody tracking over multi-year periods or its effect on long-term safety/effectiveness.
The most credible comparison of long-term safety is based on registries and real-world studies that follow patients beyond the timeframe of clinical trials.
A general evidentiary methodology statement not present in the label excerpts.
Contradictions
Important Omissions
Key label-specific safety warnings that should accompany any discussion of infection risk, including pre-treatment TB evaluation and the explicit instruction not to initiate in active TB; also live vaccine avoidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response makes several high-level infection-related claims that align directionally with labeled infection risk, but it adds many unverifiable generalizations about long-term safety signals and comparative class themes not supported by the provided prescribing information excerpts. This could mislead readers toward overly reassuring interpretations (e.g., 'no new major safety signal' and 'absence of unexpected late-emerging toxicities'), which are not verifiable from the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Numerous broad long-term safety and cross-class comparative claims are not supported by the provided COSENTYX label excerpts, including assertions of no new major safety signals and absence of late-emerging toxicities.
Suggested Improvement
Restrict statements to what is explicitly supported in the label excerpts (e.g., infection risk, opportunistic/fungal infection reporting, serious infection monitoring/discontinuation, TB evaluation, live vaccine avoidance) and avoid unverified generalizations about multi-year signal absence, frequency claims for candidiasis, and comparisons to other drug classes.